Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Cell Physiol ; 233(11): 8477-8481, 2018 11.
Artigo em Inglês | MEDLINE | ID: mdl-29856495

RESUMO

The cellular cytoskeleton is involved with multiple biological processes and is tightly regulated by multiple proteins and effectors. Among these, the RhoGTPases family is one of the most important players. RhoGTPAses are, in turn, regulated by many other elements. In the past decade, one of those regulators, the RhoGAP Rho GTPase Activating Protein 21 (ARHGAP21), has been overlooked, despite being implied as having an important role on many of those processes. In this paper, we aimed to review the available literature regarding ARHGAP21 to highlight its importance and the mechanisms of action that have been found so far for this still unknown protein involved with cell adhesion, migration, Golgi regulation, cell trafficking, and even insulin secretion.


Assuntos
Citoesqueleto/genética , Proteínas Ativadoras de GTPase/genética , Complexo de Golgi/genética , Proteínas rho de Ligação ao GTP/genética , Adesão Celular/genética , Movimento Celular/genética , Citoesqueleto/metabolismo , Proteínas Ativadoras de GTPase/metabolismo , Humanos , Secreção de Insulina/genética , Transporte Proteico/genética
2.
Front Immunol ; 4: 439, 2013 Dec 11.
Artigo em Inglês | MEDLINE | ID: mdl-24376444

RESUMO

Several reports in the literature have drawn a complex picture of the effect of treatments aiming to modulate IL2 activity in vivo. They seem to promote either immunity or tolerance, probably depending on the specific context, dose, and timing of their application. Such complexity might derive from the pleiotropic role of IL2 in T cell dynamics. To theoretically address the latter possibility, our group has developed several mathematical models for Helper, Regulatory, and Memory T cell population dynamics, which account for most well-known facts concerning their relationship with IL2. We have simulated the effect of several types of therapies, including the injection of: IL2; antibodies anti-IL2; IL2/anti-IL2 immune-complexes; and mutant variants of IL2. We studied the qualitative and quantitative conditions of dose and timing for these treatments which allow them to potentiate either immunity or tolerance. Our results provide reasonable explanations for the existent pre-clinical and clinical data, predict some novel treatments, and further provide interesting practical guidelines to optimize the future application of these types of treatments.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA